Wells Fargo
QTTB icon

Wells Fargo’s Q32 Bio QTTB Stock Holding History

Wells Fargo’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$539 Buy
+84
New +$399 ﹤0.01% 6391
2025
Q3 		– Sell
-139
Closed -$207 – 7458
2025
Q2 		$207 Sell
139
-3,519
-96% -$6K ﹤0.01% 6440
2025
Q1 		$6.04K Buy
3,658
+80
+2% +$215 ﹤0.01% 5995
2024
Q4 		$12.3K Buy
3,578
+799
+29% +$25.2K ﹤0.01% 5891
2024
Q3 		$124K Buy
2,779
+52
+2% +$1.91K ﹤0.01% 4889
2024
Q2 		$49K Buy
2,727
+2,648
+3,352% +$63.4K ﹤0.01% 5297
2024
Q1 		$1.35K Sell
79
-15
-16% -$207 ﹤0.01% 6090
2023
Q4 		$1.03K Hold
94
– – ﹤0.01% 6216
2023
Q3 		$1.97K Sell
94
-26
-22% -$530 ﹤0.01% 6095
2023
Q2 		$1.91K Hold
120
– – ﹤0.01% 6217
2023
Q1 		$2.22K Buy
120
+45
+60% +$1.12K ﹤0.01% 6208
2022
Q4 		$1.7K Sell
75
-39
-34% -$1.03K ﹤0.01% 6048
2022
Q3 		$3K Buy
114
+7
+7% +$285 ﹤0.01% 6093
2022
Q2 		$4K Sell
107
-3,365
-97% -$115K ﹤0.01% 6122
2022
Q1 		$190K Sell
3,472
-637
-16% -$39.6K ﹤0.01% 5009
2021
Q4 		$269K Buy
4,109
+1,188
+41% +$115K ﹤0.01% 5104
2021
Q3 		$413K Buy
2,921
+2,865
+5,116% +$365K ﹤0.01% 4767
2021
Q2 		$7K Sell
56
-374
-87% -$46.7K ﹤0.01% 6250
2021
Q1 		$73K Sell
430
-1,170
-73% -$246K ﹤0.01% 5632
2020
Q4 		$325K Buy
1,600
+672
+72% +$130K ﹤0.01% 4827
2020
Q3 		$178K Sell
928
-334
-26% -$74.8K ﹤0.01% 5014
2020
Q2 		$346K Buy
1,262
+370
+41% +$98.6K ﹤0.01% 4584
2020
Q1 		$250K Sell
892
-561
-39% -$172K ﹤0.01% 4537
2019
Q4 		$542K Buy
1,453
+512
+54% +$147K ﹤0.01% 4299
2019
Q3 		$307K Buy
941
+362
+63% +$123K ﹤0.01% 4712
2019
Q2 		$204K Buy
579
+164
+40% +$64.5K ﹤0.01% 4961
2019
Q1 		$207K Sell
415
-225
-35% -$101K ﹤0.01% 4805
2018
Q4 		$258K Buy
640
+297
+87% +$112K ﹤0.01% 4766
2018
Q3 		$141K Buy
343
+244
+246% +$82.9K ﹤0.01% 5196
2018
Q2 		$36K Buy
+99
New +$35.4K ﹤0.01% 5682

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's QTTB Position: Q1 2026 in Review

Wells Fargo opened a new position in Q32 Bio (QTTB) in Q1 2026: 84 shares worth $539. The stake represents ﹤0.01% of the portfolio and ranks #6391 among its holdings. This is a return to the name: Wells Fargo previously reported a position in QTTB as recently as Q2 2025.

Wells Fargo first reported a position in QTTB in Q2 2018 and has held it in 30 quarters since. The position peaked at $542K in Q4 2019. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Wells Fargo held 84 shares of Q32 Bio worth $539 as of Q1 2026.
  • Q32 Bio was a new Wells Fargo position in Q1 2026.
  • Q32 Bio made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6391 holding.
  • Wells Fargo first reported a position in Q32 Bio in Q2 2018 and has held it in 30 quarters since.
  • Wells Fargo's Q32 Bio position peaked at $542K in Q4 2019.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.